Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMoy, Beverly
dc.contributor.authorAntunes de Melo Oliveira, Ana Mafalda
dc.contributor.authorSaura Manich, Cristina
dc.contributor.authorGradishar, William
dc.contributor.authorKim, Sung‑Bae
dc.contributor.authorBrufsky, Adam
dc.date.accessioned2022-06-15T10:54:34Z
dc.date.available2022-06-15T10:54:34Z
dc.date.issued2021-07
dc.identifier.citationMoy B, Oliveira M, Saura C, Gradishar W, Kim SB, Brufsky A, et al. Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens. Breast Cancer Res Treat. 2021 Jul;188:449–458.
dc.identifier.issn1460-2156
dc.identifier.urihttp://hdl.handle.net/11351/7682
dc.descriptionHealth-related quality of life; Metastatic breast cancer; Neratinib
dc.description.abstractPurpose To characterize health-related quality of life (HRQoL) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) from the NALA phase 3 study. Methods In NALA (NCT01808573), patients were randomized 1:1 to neratinib + capecitabine (N + C) or lapatinib + capecitabine (L + C). HRQoL was assessed using seven prespecified scores from the European Organisation for Research and Treatment of Cancer Quality Of Life Questionnaire core module (QLQ-C30) and breast cancer-specific questionnaire (QLQ-BR23) at baseline and every 6 weeks. Descriptive statistics summarized scores over time, mixed models evaluated differences between treatment arms, and Kaplan–Meier methods were used to assess time to deterioration in HRQoL scores of ≥ 10 points. Results Of the 621 patients randomized in NALA, patients were included in the HRQoL analysis if they completed baseline and at least one follow-up questionnaire. The summary, global health status, physical functioning, fatigue, constipation, and systemic therapy side effects scores were stable over time with no persistent differences between treatment groups. There were no differences in time to deterioration (TTD) for the QLQ-C30 summary score between treatment arms; the hazard ratio (HR) for N + C vs. L + C was 0.94 (95% CI 0.63–1.40). Only the diarrhea score worsened significantly more in the N + C arm as compared to the L + C arm, and this remained over time (HR for TTD for N + C vs. L + C was 1.71 [95% CI 1.32–2.23]). Conclusion In NALA, patients treated with N + C maintained their global HRQoL over time, despite a worsening of the diarrhea-related scores. These results may help guide optimal treatment selection for HER2-positive MBC.
dc.language.isoeng
dc.publisherOxford University Press
dc.relation.ispartofseriesBreast Cancer Research and Treatment;188
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMama - Càncer - Tractament
dc.subjectMedicaments antineoplàstics - Ús terapèutic
dc.subjectQualitat de vida - Avaluació
dc.subject.meshBreast Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.titleNeratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s10549-021-06217-4
dc.subject.decsneoplasias de la mama
dc.subject.decs/farmacoterapia
dc.subject.decsprotocolos de quimioterapia antineoplásica combinada
dc.relation.publishversionhttps://doi.org/10.1007/s10549-021-06217-4
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Moy B] Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA. [Oliveira M, Saura C] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Gradishar W] Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA. [Kim SB] Asan Medical Center, University of Ulsan College of Medicine, Seoul, Kore. [Brufsky A] Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA
dc.identifier.pmid33909203
dc.identifier.wos000710927500019
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record